BRPI0518086A - métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação - Google Patents

métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação

Info

Publication number
BRPI0518086A
BRPI0518086A BRPI0518086-4A BRPI0518086A BRPI0518086A BR PI0518086 A BRPI0518086 A BR PI0518086A BR PI0518086 A BRPI0518086 A BR PI0518086A BR PI0518086 A BRPI0518086 A BR PI0518086A
Authority
BR
Brazil
Prior art keywords
methods
activation
cancer treatment
identification
phosphorylation
Prior art date
Application number
BRPI0518086-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Lukas C Amler
Thomas E Januario
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0518086A publication Critical patent/BRPI0518086A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
BRPI0518086-4A 2004-12-07 2005-12-06 métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação BRPI0518086A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63394104P 2004-12-07 2004-12-07
PCT/US2005/044247 WO2006063042A2 (en) 2004-12-07 2005-12-06 Selecting patients for therapy with a her inhibitor

Publications (1)

Publication Number Publication Date
BRPI0518086A true BRPI0518086A (pt) 2008-10-28

Family

ID=36177671

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518086-4A BRPI0518086A (pt) 2004-12-07 2005-12-06 métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação

Country Status (14)

Country Link
US (2) US20060121044A1 (cg-RX-API-DMAC7.html)
EP (1) EP1825001A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008523073A (cg-RX-API-DMAC7.html)
KR (1) KR20070085855A (cg-RX-API-DMAC7.html)
CN (1) CN101115849A (cg-RX-API-DMAC7.html)
AR (1) AR051524A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005314127A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0518086A (cg-RX-API-DMAC7.html)
CA (1) CA2587519A1 (cg-RX-API-DMAC7.html)
MX (1) MX2007006529A (cg-RX-API-DMAC7.html)
NO (1) NO20073487L (cg-RX-API-DMAC7.html)
RU (1) RU2007125644A (cg-RX-API-DMAC7.html)
WO (1) WO2006063042A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704796B (cg-RX-API-DMAC7.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AU2001264696B2 (en) 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
ATE446317T1 (de) 2001-05-11 2009-11-15 Ludwig Inst For Cancer Res Ltd Spezifische bindungsproteine und ihre verwendung
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US7767792B2 (en) * 2004-02-20 2010-08-03 Ludwig Institute For Cancer Research Ltd. Antibodies to EGF receptor epitope peptides
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
CA2596133C (en) * 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
US20080038271A1 (en) * 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
EP2518508A1 (en) * 2006-11-28 2012-10-31 U3 Pharma GmbH Activated HER3 as a marker for predicting therapeutic efficacy
US7825127B2 (en) * 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
CN101711284A (zh) * 2007-01-25 2010-05-19 达娜-法勃肿瘤研究所 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
CA2677108A1 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her inhibitor
EP2592156B1 (en) * 2007-06-08 2016-04-20 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2009023265A1 (en) 2007-08-14 2009-02-19 Ludwig Institute For Cancer Research Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
WO2009026705A1 (en) * 2007-08-24 2009-03-05 The University Of Western Ontario Method of diagnosing and treating osteoarthritis
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
WO2010006027A1 (en) 2008-07-08 2010-01-14 George Mason Intellectual Properties, Inc. Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
CN102753193A (zh) 2008-10-31 2012-10-24 比奥根艾迪克Ma公司 Light靶向分子及其用途
EP2513148B1 (en) * 2009-12-16 2016-08-31 AbbVie Biotherapeutics Inc. Anti-her2 antibodies and their uses
SG183532A1 (en) 2010-03-11 2012-09-27 Merrimack Pharmaceuticals Inc Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
CN107253992B (zh) 2010-05-27 2022-03-11 根马布股份公司 针对her2的单克隆抗体
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
MX347981B (es) 2010-11-01 2017-05-22 Symphogen As Composicion de anticuerpos pan-her.
CN103796677B (zh) 2011-04-20 2019-08-16 健玛保 针对her2和cd3的双特异性抗体
CA2851314A1 (en) * 2011-10-06 2013-04-11 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-erbb3 antibodies
PT4403228T (pt) 2011-10-14 2025-10-07 Hoffmann La Roche Utilizações do inibidor da dimerização de her2 pertuzumab e artigo de fabrico que inclui o mesmo
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
JP6602746B2 (ja) * 2013-03-15 2019-11-06 カポン、ダニエル・ジェイ． 非ペプチジル結合を含むハイブリッド免疫グロブリン
US9815904B2 (en) 2013-04-16 2017-11-14 Genetech, Inc. Pertuzumab variants and evaluation thereof
EP3087394A2 (en) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
ES2932285T3 (es) 2014-03-14 2023-01-17 Biomolecular Holdings Llc Compuestos útiles en la preparación de inmunoglobulina híbrida que contiene una unión distinta de peptidilo
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
CN108027360A (zh) * 2015-05-29 2018-05-11 爱科谱迅病理研究公司 用于最优癌症治疗的定量Her2蛋白质
PT3302551T (pt) 2015-05-30 2024-08-21 H Hoffnabb La Roche Ag Métodos de tratamento do cancro da mama metastático positivo para her2 não tratado previamente
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
GB201611580D0 (en) * 2016-07-01 2016-08-17 Aslan Pharmaceuticals Pte Ltd Method
CA3040913A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
JP6992081B2 (ja) 2017-03-02 2022-02-03 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
MX2022015884A (es) 2020-06-29 2023-04-03 Genentech Inc Combinacion de dosis fija de pertuzumab mas trastuzumab.

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5824311A (en) * 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
JP3040121B2 (ja) * 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) * 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
WO1999048527A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
DE69907439T3 (de) * 1998-05-06 2014-01-02 Genentech, Inc. Reinigung von proteinen durch ionenaustauschchromatographie
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
AU782325B2 (en) * 1999-05-14 2005-07-21 Genentech Inc. Treatment with anti-ErbB2 antibodies
MXPA01013395A (es) * 1999-06-25 2003-09-04 Genentech Inc Tratamiento de cancer de prostata con anticuerpos anti-erbb2.
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
BRPI0012198B8 (pt) * 1999-06-25 2021-05-25 Genentech Inc anticorpos humanizados, composição e imunoconjugado
EP2110138A1 (en) * 1999-08-27 2009-10-21 Genentech, Inc. Dosages for treatment of anti-erbB2 antibodies
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
AU2001264696B2 (en) * 2000-05-19 2007-01-04 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
AU2003273218C1 (en) * 2002-07-15 2019-01-17 F. Hoffmann - La Roche Ag Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
US20040013297A1 (en) * 2002-07-18 2004-01-22 Roger Lo Method for performing color gamut compression
CA2500255A1 (en) * 2002-10-01 2004-04-29 Epigenomics Ag Method and nucleic acids for the treatment of breast cell proliferative disorders
JP4606879B2 (ja) * 2002-11-15 2011-01-05 ジェノミック ヘルス， インコーポレイテッド Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US20040258685A1 (en) * 2002-11-21 2004-12-23 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA2530738C (en) * 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
ZA200701234B (en) * 2004-07-22 2008-12-31 Genentech Inc HER2 antibody composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008523073A (ja) * 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
CA2592177A1 (en) * 2005-01-21 2006-07-27 Genentech, Inc. Fixed dosing of her antibodies
CA2596133C (en) * 2005-02-23 2016-11-15 Genentech, Inc. Extending time to disease progression or survival in cancer patients
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20080038271A1 (en) * 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
EP2441472B1 (en) * 2006-08-21 2015-06-10 F. Hoffmann-La Roche AG Tumor therapy with an anti-VEGF antibody

Also Published As

Publication number Publication date
RU2007125644A (ru) 2009-01-20
EP1825001A2 (en) 2007-08-29
CN101115849A (zh) 2008-01-30
AR051524A1 (es) 2007-01-17
ZA200704796B (en) 2008-11-26
JP2008523073A (ja) 2008-07-03
AU2005314127A1 (en) 2006-06-15
WO2006063042A3 (en) 2007-02-08
MX2007006529A (es) 2007-06-22
KR20070085855A (ko) 2007-08-27
US20080317753A1 (en) 2008-12-25
NO20073487L (no) 2007-09-05
CA2587519A1 (en) 2006-06-15
US20060121044A1 (en) 2006-06-08
WO2006063042A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
BRPI0518086A (pt) métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
Bayat et al. Comparison of effects of LLLT and LIPUS on fracture healing in animal models and patients: A systematic review
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BRPI0907637A8 (pt) biomarcadores p53
NZ609493A (en) Diagnosis and treatments relating to th2 inhibition
MX2017014381A (es) Metodos terapeuticos y diagnosticos para cancer.
EP2114990A4 (en) EXPRESSION PROFILES OF GENES AND PROTEINS ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF EGFR-TK INHIBITORS
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
BRPI0915240A2 (pt) método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met
ECSP17025787A (es) Uso de paneles de genes mutantes de fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor de fgfr
EP2209495A4 (en) TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER
PL2492355T3 (pl) Receptor erytropoetyny ochronny dla tkanki (nepor) i sposoby zastosowania
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
CY1111612T1 (el) Μεθοδος για προβλεψη της αποκρισης σε μια θεραπευτικη αγωγη με εναν αναστολεαδιmερισmου του her
CY1116089T1 (el) Cd73 ως ενας βιοδεικτης για την παρακολουθηση της εξελιξης νοσων και εκτιμηση της αποτελεσματικοτητας θεραπειων
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
BRPI0616254B8 (pt) instrumento de inserção de implante ortopédico radiolucente
BR112012030838A2 (pt) molécula de ácido nucléico isolada que codifica uma proteína mek1 mutante tendo atividade de mek1, vetor de expressão, célula hospedeira, método de produzir uma prote ína mek1 mutante, proteína mek1 mutante isolada, método de identificar um paciente que tem câncer, método de orimizar o tratamento de um paciente que tem câncer,e, uso de um inibidor de raf e de um inibidor de mek.
WO2019075251A3 (en) Cancer score for assessment and response prediction from biological fluids
MXPA05014220A (es) Genes regulados en cancer ovarico como objetivos de pronostico y terapeuticos.
BRPI0806202A2 (pt) método para detecção de doenças neoplásticas e neurológicas em um indivìduo e instrumento
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
BR112022011328A2 (pt) Método para determinar o risco de um evento trombótico em um paciente com câncer, método para diagnosticar e tratar uma condição trombótica em um paciente com câncer, método para monitorar o risco de uma condição trombótica em um paciente com câncer em tratamento, kit, método para examinar ppia, pdia3 e pelo menos um dentre eif5a, eif4h, eif4a3, ube2n, ube2l3, ube2i e hsp70 em uma amostra de soro ou plasma e método para examinar uma combinação de marcadores em uma amostra de fluido biológico obtida de um indivíduo humano
BRPI0512336A (pt) métodos de diagnósticos para osteoporose
DE60217665D1 (de) Verfahren zur Bestimmung der Aktivität von Thymidinkinase-1 und dessen Verwendung

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.